Synthesis and study of the effect of 3-substituted chromone derivatives on changes in the activity of mitochondrial complex III under experimental cerebral ischemia

Viktoriya RUKOVITSINA 1 * (✉), Eduard OGANESYAN 1 ▼, Dmitry POZDNYAKOV 2 ▼

1 Department of Organic Chemistry, Faculty of Pharmacy, Pyatigorsk Medical and Pharmaceutical Institute, 357532 Pyatigorsk, Russia.
2 Department Pharmacology with Course of Clinical Pharmacology, Faculty of Pharmacy, Pyatigorsk Medical and Pharmaceutical Institute, 357532 Pyatigorsk, Russia.
* Corresponding Author. E-mail: pozdniackow.dmitry@yandex.ru Tel: +7-918-756-08-89

Received: 14 June 2021 / Revised: 14 January 2022 / Accepted: 17 January 2022

ABSTRACT: Chromone derivatives are characterized by an extensive spectrum of pharmacological activity and can be potentially effective neuroprotective agents. In this regard, this study evaluated the effect of eighteen new derivatives of 3-formylchromone on the change in the activity of mitochondrial complex III in ischemic and intact animals as a promising direction of neuroprotective therapy. The dependence of the level of pharmacological effect on changes in the quantum-chemical parameters (Mulliken Charge, Bond number, Theoretical valence, Unsaturated index, Electron density, Free valence index) of the molecules was also evaluated. The structure of the substances was confirmed by IR, UV and NMR spectroscopy, as well as by determining the melting point. The study made it possible to establish that, among the 3-substituted chromone derivatives, the most pronounced neuroprotective activity is possessed by compounds that do not contain halogen atoms in their structure. The leader compound can be considered 3-[(E)-3-(3,5-di-tret-butyl-4-hydroxy-phenyl) -3-oxo-prop-1-enyl]-6-methoxy-chromen-4-one, the use of which increased the activity of mitochondrial complex III by 85.2% (p <0.05) in relation to the negative control group. To the greatest extent, the influence of the test substances on the activity of the mitochondrial complex III depended on the change of Free valence index (correlation coefficient, r=0.93701)

KEYWORDS: Substituted chromone derivatives; mitochondrial complex III; neuroprotection; mitochondrial dysfunction

1. INTRODUCTION

Mitochondria are cell organelles that perform three main functions in the cell: generating ATP and maintaining energy homeostasis; regulation of the production of reactive forms of oxygen (ROS) as molecules that control epigenetic processes; control of apoptosis reactions, both external and internal cascade [1]. The leading organizational component of the mitochondrial matrix is the electron transport chain (ETC). The ETC consists of four protein supercomplexes (I-IV) localized on the inner mitochondrial membrane. Initially, complexes I and II oxidize NADH and FADH2, respectively, transferring the obtained electrons to ubiquinol, which transfers electrons to complex III. Complex III, in turn, transports electrons through the intermembrane space to cytochrome C, and, accordingly, to complex IV. Then complex IV uses electrons to reduce oxygen to water [2]. In the course of electron transport reactions, the generation of ROS is observed, and their leakage from the ETC can be noted, which leads to the initiation of oxidative stress. Complexes I and II generate ROS (mainly represented by superoxide radical) in the mitochondrial matrix, while complex III generates ROS both in the matrix and in the intermembrane space, which makes this organizational component of the ETC the leading site of ROS formation [3].

Complex III generates ROS during Q-cycle reactions (successive oxidation and reduction reactions of CoQ). In this process, ubisemiquinone in a non-enzymatic reaction can freely give an unpaired electron to oxygen, with the formation of ROS (superoxide radical). In turn, ROS are able to be released into the...
mitochondrial matrix and penetrate through the mitochondrial inner membrane. The process of ROS penetration through the inner membrane of mitochondria proceeds by two mechanisms: with the catalytic conversion of a superoxide radical into a peroxide-a more stable molecule, or with the participation of anionic mitochondrial channels [4].

Thus, a targeted pharmacological effect on mitochondrial complex III may be a promising direction in the treatment of oxidative stress and associated diseases, for example, ischemic stroke [5].

Chromone is known to be benzannulated 4H-pyranone-4. Chromone derivatives constitute one of the most numerous groups of natural compounds, of which the most studied derivatives are 2-arylchromone-flavones and 3-arylchromone-isoflavones. Representatives of these compounds are included in the main classes of flavonoids and have more than 5000 described structures, characterized by about 50 types of pharmacological activity [6]. It has now been established that the chromone nucleus is a promising basic structure for the targeted synthesis of new compounds with desired pharmacological properties. In particular, chromone derivatives are used in the field of neurodegenerative, inflammatory and infectious pathologies, as well as diabetes mellitus and cancer [7]. In addition, the antiallergic properties of chromone derivatives are widely known, which are associated with the stabilization of mast cells cell membranes [8]. In an earlier study, chromone derivatives had a positive effect on changes in mitochondrial function, normalizing the reactions of aerobic/anaerobic metabolism, which served as the basis for choosing representatives of a number of derivatives of 3-formylchromone as the test objects [9].

Considering also that the structural diversity of the types, number and position of substituents attached to the main chromone nucleus is important for a directed change in the physical, chemical and pharmacological properties of the target compounds [10], we carried out this work.

2. RESULTS

2.1 Results of assessing the effect of the studied compounds on the change in the activity of mitochondrial complex III

The effect of the test-compounds on the activity of the mitochondrial complex III was assessed in ischemic and intact animals (Table 1). As a result, it was found that the administration of the test-substances to intact animals did not have a significant effect on changes in the activity of ubiquinolcytochrome-c-oxidoreductase. At the same time, in rats with cerebral ischemia, which did not receive pharmacological support, a decrease in the activity of this respiratory complex by 52% (p <0.05) was noted in relation to SO (sham-operated) animals (Table 1). On the background of the administration of the CoQ10, the catalytic properties of ubiquinolcytochrome-c-oxidoreductase in comparison with the NC (negative control) group of rats increase by 39% (p <0.05). The use of test compounds C3ACL; C3AF; C3AI; C3A6Ac and C3ACLNOH; C3AACP1; C3AACP2; C3AACP3; C3AACP4; C3AACP5 C3AACP6; C3AACP7 also increased the activity of mitochondrial complex III by 42.3%; 64.2%; 30.9%; 25.2%; 26%; 31.7%; 43.9%; 67.5%; 53.7%; 41.5%; 46.3%; 60.2% and 85.2% respectively (all indicators p <0.05 relative to the NC group of rats). At the same time, the activity of ubiquinolcytochrome-c-oxidoreductase in animals that received compounds C3AACP2 and C3AACP7 was higher than that in rats that received CoQ10 (Table 2) by 20.4% (p <0.05) and 33.3% (p <0.05) respectively.
Table 1. Influence of the test compounds and the reference drug on the change in the activity of the mitochondrial complex III in the brain tissue in rats against the background of focal cerebral ischemia and in intact animals

| Group         | Intact animals | Ischemia   |
|---------------|----------------|------------|
| SO            | 24.8±1.572     | 25.6±2.225 |
| NC            | -              | 12.3±1.276#|
| CoQ<sub>10</sub> | 24.2±1.895     | 17.1±2.343*|
| C3A           | 24.3±2.56      | 14.4±2.398*|
| C3ACL         | 23.7±2.894     | 17.5±1.817*|
| C3AF          | 22.7±1.851     | 20.2±2.535*|
| C3AI          | 23.9±2.687     | 19.9±2.45* |
| C3A6Ac        | 25.7±2.098     | 12.4±2.635 |
| C3A7Ac        | 24.9±1.68      | 14.2±2.541 |
| C3AOC<sub>H</sub>3 | 24.7±1.246     | 12.2±2.624 |
| C3ACH<sub>H</sub>3Phen | 25.9±2.053 | 1.1±1.108 |
| C3ANOH        | 24.6±2.867     | 13.4±1.908 |
| C3AFNOH       | 23.6±2.249     | 15.5±1.562*|
| C3ACLNOH      | 22.5±2.038     | 16.2±2.747*|
| C3AACP1       | 24.3±2.4       | 17.7±1.291*|
| C3AACP2       | 25.1±2.217     | 20.6±2.09* Δ|
| C3AACP3       | 24.5±2.986     | 18.9±1.063*|
| C3AACP4       | 24.2±2.639     | 17.4±2.589*|
| C3AACP5       | 25.3±2.854     | 18±1.564*  |
| C3AACP6       | 23.3±2.417     | 19.7±2.868*|
| C3AACP7       | 24.7±2.635     | 22.8±1.687* Δ|

Note: SO – sham-operated rats; NC - negative control rats; # - significantly relative to the SO animals (Newman-Keuls test, p <0.05); * - significantly relative to the NC group of animals (Newman-Keuls test, p <0.05); Δ - significantly relative to the group of animals treated with CoQ<sub>10</sub> (Newman-Keuls test, p <0.05).

2.2. Correlation analysis results

Table 2 shows the summary quantum-chemical parameters used in the correlation analysis. The data of the pharmacological experiment showed a significant difference in the effect of compounds that do not contain halogens compared to that of halogen-containing derivatives. In this regard, in the correlation analysis, both subgroups of test-compounds was carried out (Table 3).
Table 2. Total values of quantum chemical parameters

| Compound     | Mulliken Charges, (a.u.) | Bond numbers (Nμ) | Theoretical valence (Vμ) | Unsaturated index (IUA) | Electron density (ED) | Free valence index (Fμ) |
|--------------|--------------------------|-------------------|--------------------------|-------------------------|----------------------|------------------------|
| C3A          | -0.96                    | 43.662            | 45.695                   | 2.033                   | 58.9557              | 9.531                  |
| C3ACL        | -1.26                    | 49.269            | 51.558                   | 2.289                   | 69.2631              | 10.68                  |
| C3AF         | -1.4                     | 54.773            | 57.575                   | 2.802                   | 79.4021              | 11.67                  |
| C3AI         | -1.43                    | 54.592            | 57.437                   | 2.845                   | 79.4296              | 11.843                 |
| C3A6Ac       | -0.843                   | 44.591            | 46.768                   | 2.177                   | 65.8429              | 5.598                  |
| C3A7Ac       | -0.841                   | 44.62             | 46.816                   | 2.196                   | 65.8411              | 9.577                  |
| C3AOC13H3    | -2.127                   | 72.609            | 75.968                   | 3.359                   | 93.1269              | 16.452                 |
| C3ANOH       | -1.33                    | 46.663            | 48.8                     | 2.14                    | 64.3331              | 9.421                  |
| C3AFNO1H     | -1.22                    | 46.588            | 49.873                   | 3.285                   | 71.2223              | 9.492                  |
| C3ACLNOH     | -1.22                    | 47.632            | 49.919                   | 2.287                   | 71.2211              | 9.475                  |
| C3AACP1      | -2.01                    | 74.135            | 77.33                    | 3.195                   | 92.0069              | 16.737                 |
| C3AACP2      | -2.66                    | 81.896            | 85.212                   | 3.316                   | 100.656              | 18.435                 |
| C3AACP3      | -2.56                    | 79.519            | 83.11                    | 3.591                   | 94.3222              | 17.882                 |
| C3AACP4      | 2.0561                   | 78.8170           | 80.4190                  | 1.6020                  | 105.0559             | 17.027                 |
| C3AACP5      | -2.3471                  | 80.7590           | 84.3970                  | 3.6380                  | 112.3472             | 17.838                 |
| C3AACP6      | -2.48                    | 81.478            | 85.155                   | 3.677                   | 108.4686             | 18.149                 |
| C3AACP7      | -4.86                    | 112.744           | 116.857                  | 4.113                   | 142.8623             | 24.624                 |

From the data in the table 3, it follows that the correlation coefficients for compounds that do not contain halogens are significantly higher than for halogenated derivatives. The maximum values of r are observed when analyzing such parameters as the free valence index (Fμ), electron density, and unsaturation index (IUA). Thus, when studying the structure - activity relationship, the most reliable results are achieved for chromone derivatives that do not contain halogens, and the Fμ parameters and electron density are used in the correlation equations.

Table 3. The value of the correlation coefficients

| Parameter         | With halogen-containing compounds | Without halogen-containing compounds |
|-------------------|-----------------------------------|-------------------------------------|
|                   | r                                 | r                                  |
| a.u.              | 0.3737                            | 0.7877                             |
| Nμ                | 0.74010                           | Nμ                                 |
| Vμ                | 0.73927                           | Vμ                                 |
| IUA               | 0.51634                           | IUA                                |
| ED                | 0.77884                           | ED                                 |
| Fμ                | 0.76814                           | Fμ                                 |

Note: a.u - Mulliken Charges; Nμ - Bond numbers; Vμ - Theoretical valence; IUA - Unsaturated index; ED- Electron density;Fμ - Free valence index.
3. DISCUSSION

Globally, ischemic stroke is the second leading cause of death and the first cause of disability in the adult population. The «gold standard» in the treatment of this pathological condition is the fastest possible recanalization of the vessel, achieved by intravenous administration of tissue plasminogen activator (t-PA). Nevertheless, this pharmacotherapeutic approach has drawbacks, which include a small «therapeutic window» and the development of post-reperfusion complications [11]. In this regard, a number of attempts to improve reperfusion treatment have been made, including through the use of adjuvants, for example, neuroprotective agents, which are currently being actively studied by the world scientific community [12]. The main direction of the action of neuroprotectors is the elimination of pathogenetic pathways of neuronal damage during ischemia, for example, oxidative stress, the activity of which directly depends on the adequate course of electron transport reactions in the mitochondrial ETC [13].

The mitochondrial respiratory chain consists of four multimeric complexes that catalyze redox reactions, with the participation of NADH and FADH₂ as electron donors, which ultimately reduces molecular oxygen to water. This electron transfer is associated with the formation of a proton electrochemical gradient required for the condensation of ADP and phosphate, and, accordingly, the formation of ATP. Complex III or ubiquinolcytochrome-c-oxidoreductase is the center of the respiratory chain, transferring electrons from coenzyme Q to cytochrome C [14]. Dysfunction of complex III leads to the development of irreversible metabolic disorders that mediate a high degree of cellular damage. Thus, when the catalytic reactions of complex III are suppressed, there is overproduction of free radicals, a decrease in ATP synthesis, the formation of a mitochondrial pore of transient permeability with an increased influx of ionized calcium and cell death as a result of apoptosis or pyroptosis [15]. In this regard, the dysfunction of complex III has an extremely negative effect on the state of organs with high metabolic activity, for example, the brain. At the same time, suppression of the physiological activity of ubiquinolcytochrome c-oxidoreductase is undesirable in view of the catastrophic drop in ATP synthesis in cells with normal metabolism [16].

The study showed that the use of newly synthesized 3-substituted chromone derivatives at a dose of 40 mg / kg per os increases the activity of mitochondrial complex III in the brain of animals with reproduced cerebral ischemia, but does not change the activity of this supercomplex in rats without pathological background, which can be evidence of the regulatory action of 3-substituted chromone derivatives in relation to ubiquinolcytochrome-c-oxidoreductase. At the same time, a regularity was noted that the inclusion of halogen atoms in the target structure significantly worsens the pharmacological effect. In this connection, a correlation analysis was carried out of the dependence of the regulatory capabilities of the studied compounds in relation to complex III and quantum-chemical parameters that most fully characterize the features of the molecular structure. This analysis showed that, with a high degree of probability, halogen atoms worsen the pharmacotherapeutic response to the administration of 3-substituted chromone derivatives, with its consistently high indicators in a number of substances that do not contain halogens in their structure. At the same time, the activity of the compounds under study largely depends on the value of the free valence index (r = 0.93701). Based on the Fₐ value, one can draw conclusions about the reactivity of molecules containing n-bonds: the larger the Fₐ value, the higher the probability for the attachment of neutral particles, which is most important for the mitochondria-oriented action of pharmacologically active substances [17]. At the same time, it is known that halogen atoms, being in the aromatic nucleus, have a strong negative inductive effect (-I effect), clearly prevailing over a weak positive mesomeric effect (+ M effect), i.e. -I >> + M, which probably distorts the n-electron cloud and leads to a decrease in therapeutic efficacy [18].

4. CONCLUSION

The study showed that among the studied 3-substituted chromone derivatives, the highest regulatory activity in relation to ubiquinolcytochrome-c-oxidoreductase is possessed by 3 - [(E) -3- (3,5-di-tert-butyl-4-hydroxy-phenyl) - 3-oxo-prop-1-enyl] -6-methoxy-chromen-4-one, the use of which contributed to the restoration of mitochondrial complex III (the activity was 85.2% higher (p <0.05) in relation to the group of negative control). The calculated correlation coefficients of the activity level from changes in the quantum-chemical parameters of molecules showed that the inclusion of halogens in the target structure leads to a significant decrease in the pharmacological effect. The above facts allow us to assert that, in order to achieve mitochondrial effects in predicting new compounds that are 3-substituted chromone derivatives, it is not advisable to introduce halogens into the aromatic nucleus, be it annelated or as an acetophenone fragment.
5. MATERIALS AND METHODS

5.1. Synthesis of target compounds

The synthesis of 3-formylchromone is carried out according to a well-known scheme using Vilsmeier's reagent. According to this scheme (Figure 1), 3-formylchromone was obtained; 6-chloro-3-formylchromone, 6-fluoro-3-formylchromone, 6-iodo-3-formylchromone, 6-acetoxy-3-formylchromone, 7-acetoxy-3-formylchromone, 7-methoxy-3-formylchromone. 2-[methyl (phenyl) amino]-4-oxo-4H-1-benzopyran-3-carbaldehyde was obtained by the reaction of 2-anilino-3-formylchromone and methyl iodide. The oximes of the corresponding derivatives of 3-formylchromone were obtained by reaction with hydroxylamine (Figure 2) [19]. The following reagents were used during the synthesis: phosphorus (V) oxychloride POCl₃ (99 %, Merk), anhydrous dimethylformamide (99 %, Merk), anhydrous acetone (Pancreac), petroleum ether (Pancreac), hydroxylamine hydrochloride (99 %, Merk). The compounds were recrystallized fivefold from absolute ethanol.

![Figure 1. Scheme of the 3-formylchromone synthesis](image1)

![Figure 2. Scheme of the oximes of the corresponding derivatives of 3-formylchromone) synthesis](image2)

Derivatives of 1-phenyl-3-oxopropen-1-yl-1 (-4H-1-benzopyran-4-one) were obtained in the reaction of 3-formylchromone and the corresponding acetophenone. 3-[(E)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-3-oxo-prop-1-enyl]-6-methoxy-chromen-4-one was obtained in reaction 6-methoxy-3-formylchromone and 3,5-di-tert-butyl-4-hydroxyacetophenone (Figure 3) [19]. The following reagents were used during the synthesis: acetophenones (Sigma-Aldrich), glacial acetic acid (Pancreac), concentrated sulfuric acid (Pancreac). The compounds were recrystallized fivefold from absolute ethanol.

![Figure 3. Scheme of the 1-phenyl-3-oxopropen-1-yl-1 (-4H-1-benzopyran-4-one) synthesis](image3)

The substances obtained were identified by IR, UV and ¹H NMR spectroscopy, as well as using physicochemical methods of analysis (determination of the melting point). NMR spectroscopy (the substances were dissolved in dimethyl sulfoxide without heating) was performed using the NTEGRA SPECTRA complex.
(Russia), IR (in vaseline oil) and UV (the substances were dissolved in dimethyl sulfoxide without heating, absorbance was measured against pure dimethyl sulfoxide) spectroscopy was performed using the systems of the FTIR spectrometer FSM-1201 (Russia) and the spectrophotometer SF-102 (Russia). The melting point of the analyzed samples was evaluated on an M-560 analyzer with the use of quartz glass capillaries.

The structural formulas of the test-compounds are given in Table 4.

3-formylchromone (C3A)

Yield -85%. $^1$H NMR (400 MHz, DMSO-d6), $\delta$ 7.43-7.55 (m, 2H, Ar); 7.73-7.79 (m, 1H, Ar); 8.29 (dd, 1H, Ar); 8.55 (s, 1H, Ar); 10.38 (s, $^1$H, CHO); IR spectrum, v C = O (CHO) 1695 cm$^{-1}$; v C = O 1650 cm$^{-1}$, v C = C 1620 cm$^{-1}$ (vase oil); UV spectrum: $\lambda_{max}$ 203, 223, 295 nm (ethanol); Tm 165°C. Elemental analysis data (%) for C$_{10}$H$_{12}$O$_{5}$ (174.15): Found: C, 68.5; H, 3.9; O, 27.6. Calculated: C, 69; H, 3.5; O, 27.6.

6-chloro-4-oxo-4H-1-benzopyran-3-carbaldehyde (C3ACL)

Yield -75%. $^1$H NMR (400 MHz, DMSO-d6), $\delta$ 7.43-7.55 (m, 2H, Ar); 7.73-7.79 (m, 1H, Ar); 8.29 (dd, 1H, Ar); 8.55 (s, 1H, Ar); 10.38 (s, 1H, CHO); Tm 167-168°C; IR spectrum, v C = O (CHO) 1695, v C = O chromone 1660, v C = C 1605 cm$^{-1}$ (vase oil); UV spectrum: $\lambda_{max}$ 203, 224, 302 nm (ethanol). Elemental analysis data (%) for C$_{10}$H$_{12}$ClO$_{5}$ (208.59): Found: C, 58; H, 1.9; Cl, 16.9; O, 25.4. Calculated: C, 57.6; H, 2.4; Cl, 17; O, 23.

6-fluoro-4-oxo-4H-1-benzopyran-3-carbaldehyde (C3AF)

Yield -67%. $^1$H NMR (400 MHz, DMSO-d6), $\delta$ 7.47-7.52 (m; 1H; Ar); 7.58-7.61 (q; 1H, Ar); 7.69-7.9 (q; 1H, Ar); 8.57 (s; 1H, Ar); 10.37 (s; 1H, CHO); Tm 152-154°C; IR spectrum, v C = O (CHO) 1695, C = O chromone 1655, C = C 1605 cm$^{-1}$ (vase oil); UV spectrum: $\lambda_{max}$ 203, 224, 302 nm (ethanol). Elemental analysis data (%) for C$_{10}$H$_{12}$F$_{5}$O$_{5}$ (192.14): Found: C, 62.3; H, 2.5; F, 9.8; O, 25.4. Calculated: C, 62.5; H, 2.6; F, 9.9; O, 25.

6-iodo-4-oxo-4H-1-benzopyran-3-carbaldehyde (C3AI)

Yield -81%. $^1$H NMR (400 MHz, DMSO-d6), $\delta$ 7.28 (s; 1H, Ar); 8.49 (s; 1H, Ar); 8.59 (d; 1H, Ar); 8.62 (s; 1H, Ar); 10.37 (s; 1H, CHO). $^1$H NMR (400 MHz, DMSO-d6): $\delta$ = 7.60 (d, 1H; J = 8.8 Hz), 8.18 (dd, 1H; J = 2.4 and 8.8 Hz), 8.37 (d, 1H; J = 2.4 Hz), 8.95 (s, 1H), 10.10 (s, 1H); Tm - 219°C; IR spectrum, v C = O (CHO) 1695, v C = O chromone 1660, v C = C 1605 cm$^{-1}$ (vase oil); UV spectrum: $\lambda_{max}$ 248, 286, 325 nm (ethanol). Elemental analysis data (%) for C$_{10}$H$_{12}$I$_{5}$O$_{5}$ (300.04): Found: C, 39.7; H, 2.1; I, 42; O, 16.3. Calculated: C, 40; H, 1.7; I, 42.3; O, 16.

3-formyl-4-oxo-4H-1-benzopyran-6-yl acetate (C3A6Ac)

Yield -65%. $^1$H NMR (400 MHz, DMSO-d6), $\delta$ 2.39 (s; 3H, CH3); 7.53 (dd, 1H, Ar); 7.59 (dd, 1H, Ar); 8.02 (d; 1H, Ar); 8.57 (s; 1H, Ar); 10.39 (s; 1H, CHO); Tm 153°C; IR spectrum, v C = O (CHO) 1698, C = O 1649, OCOCH$_{3}$ 1770 cm$^{-1}$ (vase oil); UV spectrum: $\lambda_{max}$ 203, 227, 304 nm (ethanol) Elemental analysis data (%) for C$_{12}$H$_{14}$O$_{5}$ (232.18): Found: C, 62.3; H, 3.6; O, 34.6. Calculated: C, 62.1; H, 3.5; O, 34.5.

3-formyl-4-oxo-4H-1-benzopyran-7-yl acetate (C3A7Ac)

Yield -69%. $^1$H NMR (400 MHz, DMSO-d6), $\delta$ 2.39 (s; 3H, CH3); 7.27 (d; 1H, Ar); 7.40 (s; 1H, Ar); 8.34 (d; 1H, Ar); 8.55 (s; 1H, Ar); 10.40 (s; 1H, CHO); Tm 154-155°C; IR spectrum, v C = O (CHO) 1696, C = O 1647, OCOCH$_{3}$ 1769 cm$^{-1}$ (vase oil); UV spectrum: $\lambda_{max}$ 203, 223, 293 (ethanol). Elemental analysis data (%) for C$_{12}$H$_{14}$O$_{5}$ (232.18): Found: C, 62.3; H, 3.6; O, 34.6. Calculated: C, 62.1; H, 3.5; O, 34.5.

7-methoxy-4-oxo-4H-1-benzopyran-3-carbaldehyde (C3AOCH3)

Yield -67%. $^1$H NMR (400 MHz, DMSO-d6) $\delta$ 3.93 (s; 3H, OCH3); 6.93-7.55 (s; 1H, Ar); 7.07 (dd, 1H, Ar); 8.21 (d; 1H, Ar); 8.50 (s; 1H, Ar); 10.39 (s; 1H, CHO); Tm 195°C; IR spectrum, v C = O (CHO) 1695, C = O chromone 1655, C = C 1605 cm$^{-1}$ (petrolatum oil); UV spectrum: $\lambda_{max}$ 211, 246, 295 (ethanol). Elemental analysis data (%) for C$_{13}$H$_{15}$O$_{4}$ (204.18): Found: C, 64.3; H, 4.1; O, 31.5. Calculated: C, 64.7; H, 3.9; O, 31.3.
2- [methyl (phenyl) amino] -4-oxo-4H-1-benzopyran-3-carbaldehyde (C3ACH3Phen)

Yield −85%. 1H NMR (400 MHz, δ, ppm in DMSO-d6: 4.07 (s, 3H, CH3); 7.41-7.46 (m, 5H, Ar); 7.61-7.67 (m, 3H, Ar); 7.95 (d, 1H, Ar); 10.14 (s, 1H, CHO). Tm 168-169 ºC; UV spectrum λmax 325, 286, 248 nm (CH3OH); IR spectrum (KBr) 1670, 1631, 1621, 1518 cm⁻¹. C = O (CHO) 1664, C = C 1623

3 - [(E) - (hydroxyimino) methyl] -4H-1-benzopyran-4-one (C3ANOH)

Yield −42%. 1H NMR (400 MHz, DMSO-d6) δ 11.43 (s, 1H, OH), 8.69 (s, 1H, CH = N), 8.14 - 8.06 (m, 2H, ArH), 7.85 (dd, J = 8.6, 7.1, 1.7 Hz, 1H, ArH), 7.70 (d, J = 8.5 Hz, 1H, ArH), 7.58 - 7.50 (m, 1H, ArH); Tm = 116-117 ºC; IR spectrum, ν C = O (CHO) 1660, C = N 945, C = C 1618 cm⁻¹ (liquid petroleum); UV spectrum: λmax 216, 250, 307 (ethanol). Elemental analysis data (%) for C16H17NO3 (289.31): Found: C, 63.3; H, 3.9; N, 7.3; O, 25.5. Calculated: C, 63.5; H, 3.7; N, 7.4; O, 25.4.

(3E)-6-fluoro-4-oxo-chromene-3-carbaldehyde oxime (C3AFNOH)

Yield −92%. 1H NMR spectrum (400 MHz), δ, ppm in DMSO-d6: 7.59-7.82 (m; 3H; Ar); 8.05 (s, 1H, Ar); 8.69 (d, 1H, CH); 11.45 (s, 1H, OH); Tm = 199-200 ºC; IR spectrum, ν C = O (CHO) 1652, C = N 954, C = C 1623 cm⁻¹ (vase oil); UV spectrum: λmax 202, 253, 310 (ethanol). Elemental analysis data (%) for C16H16FNO3 (270.16): Found: C, 58.3; H, 2.6; F 9.0; N, 6.7; O, 23.5. Calculated: C, 58.2; H, 2.9; F 9.2; N, 6.8; O, 23.2.

(3E)-6-chloro-4-oxo-chromene-3-carbaldehyde oxime (C3ACLNOH)

Yield −80%. 1H NMR spectrum (400 MHz, δ, ppm in DMSO-d6: 7.74-7.87 (m; 3H; Ar); 8.02-8.06 (q, 1H, Ar); 8.67 (d, 1H, CH); 11.55 (s, 1H, OH); Tm = 199-200 ºC; IR spectrum, ν C = O (CHO) 1656, C = N 954, C = C 1623 cm⁻¹ (vase oil); UV spectrum: λmax 203, 253, 316 (ethanol). Elemental data analysis (%) for C16H16ClNO3 (223.61): Found: C, 53.3; H, 2.6; Cl 16.0; N, 6.5; O, 21.7. Calculated: C, 53.7; H, 2.7; Cl 15.9; N, 6.3; O, 21.5.

3 - [(1E)-3-oxo-3-phenylprop-1-en-1-yl] -4H-1-benzopyran-4-one (C3AACP1)

Yield −21%. 1H NMR (400 MHz, Chloroform-d) δ 8.70 (d, J = 15.4 Hz, 1H), 8.32 (d, J = 7.9 Hz, 1H), 8.22 (s, 1H), 8.12 (d, J = 7.9 Hz, 2H), 7.73 (t, J = 7.8 Hz, 1H), 7.59 (t, J = 6.9 Hz, 1H), 7.50 (q, J = 7.5 Hz, 5H); Tm = 171-172 ºC; IR spectrum, ν C = O (propene) 1661, C = O (CHO chromene) 1612, C = C (propene) 1589, C = C (propene) 1003 cm⁻¹ (liquid petrolatum); UV spectrum: λmax 309, 280, 229 (ethanol). Elemental analysis data (%) for C18H18O2 (276.2): Found: C, 78.1; H, 4.3; O, 17.6. Calculated: C, 78; H, 4.4; O, 17.4.

3 - [(1E)-3-(3,4-dimethylphenyl) -3-oxoprop-1-en-1-yl] -4H-1-benzopyran-4-one (C3AACP2)

Yield −33%. 1H NMR (400 MHz, Chloroform-d) δ 8.68 (d, J = 15.3 Hz, 1H, ArH), 8.32 (dd, J = 8.1, 1.7 Hz, 1H, ArH), 8.21 (s, 1H, ArH), 7.88 (d, J = 10.9Hz, 2H, ArH), 7.78 - 7.67 (m, 1H, CH = CH), 7.50 (dd, J = 14.7, 7.5 Hz, 3H, ArH), 7.28 (d, J = 5.2 Hz, 1H, CH = CH), 2.35 (d, J = 5.2Hz, 6H, CH3); Tm = 181-182 ºC; IR spectrum, ν C = O (propene) 1665, C = O (CHO chromene) 1603, C = C (propene) 1577, C = C (propene) 999 cm⁻¹ (liquid petrolatum); UV spectrum: λmax 230, 309 (ethanol). Elemental analysis data (%) for C20H16O3 (304.3): Found: C, 78.8; H, 5.4; O, 15.8. Calculated: C, 78; 9H, 5.3; O, 15.8.

3 - [(1E)-3-(2-hydroxy-5-methylphenyl) -3-oxoprop-1-en-1-yl] -4H-1-benzopyran-4-one (C3AACP3)

Yield −60%. 1H NMR (400 MHz, Chloroform-d) δ 12.70 (s, 1H, OH), 8.82 (d, J = 15.2 Hz, 1H, ArH), 8.34 (dd, J = 8.0, 1.7 Hz, 1H, ArH), 8.24 (s, 1H, ArH), 7.81 (d, J = 2.2 Hz, 1H, ArH), 7.79 - 7.71 (m, 1H, C = H), 7.58 - 7.48 (m, 3H, ArH), 7.32 (dd, J = 8.4, 2.2 Hz, 1H, ArH), 6.93 (d, J = 8.4 Hz, 1H, C = H), 2.37 (s, 3H, CH3); Tm = 205 ºC; IR spectrum, ν C = O (propene) 1665, C = O (CHO chromene) 1644, C = C (propene) 1573, C = C (propene) 998 cm⁻¹ (liquid petrolatum); UV spectrum: λmax 312, 229 (ethanol). Elemental analysis data (%) for C16H15O3 (306.31): Found: C, 74.3; H, 4.8; O, 20.9. Calculated: C, 74; 5 H, 4.6; O, 20.9.

3 - [(1E)-3-(5-fluoro-2-hydroxyphenyl) -3-oxoprop-1-en-1-yl] -4H-1-benzopyran-4-one (C3AACP4)

415
Yield - 47%. ¹H NMR (400 MHz, Chloroform-d) δ 12.58 (s, 1H, OH), 8.76 (d, J = 15.1 Hz, 1H, ArH), 8.38 - 8.31 (m, 1H, ArH), 7.81 - 7.69 (m, 2H, ArH), 7.62 - 7.49 (m, 4H, ArH), 7.00 (dd, J = 9.2, 4.8 Hz, 1H, C = H); Tm = 208°C; IR spectrum, ν C = O (propenone) 1661, C = O (CHO chromone) 1612, C = C (propenone) 1577, C = C 1623 cm⁻¹ (liquid petrolatum); UV spectrum: λmax 315, 234 (ethanol). Elemental analysis data (%) for C₁₈H₁₁FO₄ (310.3): Found: C, 69.6; H, 3.5; F 6.2; O, 20.7. Calculated: C, 69; 7 H, 3.6; F 6.1; O, 20.6.

3 - [(1E)-3-(2-hydroxy-3-iodo-5-methylphenyl) -3-oxoprop-1-en-1-yl] -4H-1-benzopyran-4-one (C3AACP5)

Yield - 60%. ¹H NMR (400 MHz, Chloroform-d) δ 13.63 (s, 1H, OH), 8.82 (d, J = 15.1 Hz, 1H, ArH), 8.31 (dd, J = 8.0, 1.7 Hz, 1H, CH = CH), 8.23 (s, 1H, CH = CH), 7.81 (s, 2H, ArH), 7.78 - 7.72 (m, 1H, CH = CH), 7.60 - 7.47 (m, 3H, ArH), 2.34 (s, 3H, CH₃); Tm = 223°C; IR spectrum, ν C = O (propenone) 1650, C = O (CHO chromone) 1628, C = C (propenone) 1554, C = C (propenone) 979 cm⁻¹ (liquid petrolatum); UV spectrum: λmax 322, 238 (ethanol). Elemental analysis data (%) for C₁₉H₁₃IO₄ (432.2): Found: C, 52.7; H, 3.1; I 29.3; O, 14.9. Calculated: C, 52; 8 H, 3; I 29.4; O, 14.8.

3 - [((E))-3-(2-hydroxy-4-methoxyphenyl) -3-oxoprop-1-en-1-yl] -4H-1-benzopyran-4-one (C3AACP6)

Yield - 60%. ¹H NMR (400 MHz, Chloroform-d) δ 12.48 (s, 1H, OH), 8.79 (d, J = 15.1 Hz, 1H, ArH), 8.34 (dd, J = 8.0, 1.7 Hz, 1H, CH = CH), 8.25 (s, 1H, ArH), 7.76 (ddd, J = 8.7, 7.0, 1.8 Hz, 1H, ArH), 7.60 - 7.47 (m, 4H, ArH), 7.16 (dd, J = 9.0, 3.0 Hz, 1H, CH = CH), 6.98 (d, J = 9.1Hz, 1H, ArH), 3.89 (s, 3H, CH₃); Tm = 201°C; IR spectrum, ν C = O (propenone) 1663, C = O (CHO chromone) 1644, C = C (propenone) 1592, C = C (propenone) 980 cm⁻¹ (liquid petrolatum); UV spectrum: λmax 395, 313, 231 (ethanol). Elemental analysis data (%) for C₁₉H₁₄O₅ (322.3): Found: C, 70.7; H, 4.5; O, 24.9. Calculated: C, 70; 8 H, 4.4; O, 24.8.

3 - [((E))-3-(3,5-di-tert-butyl-4-hydroxy-phenyl) -3-oxo-prop-1-enyl] -6-methoxy-chromen-4-one (C3AACP7)

Yield - 22% ¹H NMR spectrum (400 MHz, δ, ppm in DMSO-d6: 1.53 (s, 18H, 6CH₃); 3.95 (s, 3H, OCH₃); 5.79 (s, 1H, C = H); 7.28-7.32 (d, J = 15.3, 1H, C = H); 7.46-7.48 (d, J = 3.1, 2H, ArH); 7.68-7.69 (d, J = 3.0, 1H, chromone); 8.02 (s, 2H, chromone); 8.21 (s, 1H, chromone); 8.64 (d, 1H, OH).Tm. 238°C; IR spectrum, ν C = O (propenone) 1661, C = O (CHO chromone) 1636, C = C (propenone) 1593, C = C (propenone) 998 cm⁻¹ (petrolatum. oil); UV spectrum: λmax 243, 325 (ethanol). Elemental analysis data (%) for C₂₇H₂₆O₅ (434.5): Found: C, 74.5; H, 7.1; O, 18.4. Calculated: C, 74; 6 H, 7; O, 18.4.
Table 4. Test-compounds formulas.

| Formula | IUPAC | Laboratory code |
|---------|-------|-----------------|
| ![Formula](image1) | 3-formylchromone | C3A |
| ![Formula](image2) | 6-chloro-4-oxo-4H-1-benzopyran-3-carbaldehyde | C3ACL |
| ![Formula](image3) | 6-fluoro-4-oxo-4H-1-benzopyran-3-carbaldehyde | C3AF |
| ![Formula](image4) | 6-iodo-4-oxo-4H-1-benzopyran-3-carbaldehyde | C3AI |
| ![Formula](image5) | 3-formyl-4-oxo-4H-1-benzopyran-6-yl acetate | C3A6Ac |
| ![Formula](image6) | 3-formyl-4-oxo-4H-1-benzopyran-7-yl acetate | C3A7Ac |
| ![Formula](image7) | 3-methoxy-4-oxo-4H-1-benzopyran-3-carbaldehyde | C3AOCH3 |
| ![Formula](image8) | 2- [(methyl (phenyl) amino) -4-oxo-4H-1-benzopyran-3-carbaldehyde | C3ACH3Ph en |
| ![Formula](image9) | 3 - [(E) - (hydroxyimino) methyl] -4H-1-benzopyran-4-one | C3ANOH |
| ![Formula](image10) | (3E) -6-fluoro-4-oxo-chromene-3-carbaldehyde oxime | C3AFNOH |
| ![Formula](image11) | (3E) - 6-chloro-4-oxo-chromene-3-carbaldehyde oxime | C3ACLNOH |
| ![Formula](image12) | 3 - [(1E) -3-oxo-3-phenylprop-1-en-1-yl] -4H-1-benzopyran-4-one | C3AACP1 |
| ![Formula](image13) | 3 - [(1E) -3- (3,4-dimethylphenyl) -3-oxoprop-1-en-1-yl] -4H-1-benzopyran-4-one | C3AACP2 |
Table 4. Test-compounds formulas. (continued)

| Formula | IUPAC | Laboratory code |
|---------|-------|-----------------|
| ![Formula 1](image1.png) | 3 - [(1E) -3- (2-hydroxy-5-methylphenyl) -3-oxoprop-1-en-1-yl] -4H-1-benzopyran-4-one | C3ACCP3 |
| ![Formula 2](image2.png) | 3 - [(1E) -3- (5-fluoro-2-hydroxyphenyl) -3-oxoprop-1-en-1-yl] -4H-1-benzopyran-4-one | C3ACCP4 |
| ![Formula 3](image3.png) | 3 - [(1E) -3- (2-hydroxy-3-iodo-5-methylphenyl) -3-oxoprop-1-en-1-yl] -4H-1-benzopyran-4-one | C3ACCP5 |
| ![Formula 4](image4.png) | 3 - [(1E) -3- (2-hydroxy-4-methoxyphenyl) -3-oxoprop-1-en-1-yl] -4H-1-benzopyran-4-one | C3ACCP6 |
| ![Formula 5](image5.png) | 3 - [(E) -3- (3,5-di-tert-butyl-4-hydroxy-phenyl) -3-oxo-prop-1-enyl] -6-methoxy-chromen-4-one | C3ACCP7 |

5.2. Laboratory animals

Evaluation of pharmacological activity was performed on male Wistar rats weighing 200-220 grams, 3 months (n = 10 in each experimental group). The animals were obtained from the Rappolovo laboratory animal nursery (Russia, Leningrad region) and during the experiment were kept under controlled conditions in the laboratory of living systems of the Pyatigorsk Medical and Pharmaceutical Institute. The maintenance and all manipulations carried out with the animals complied with the recommendations of Directive 2010/63 / EU of the European Parliament and of the council on the protection of animals used for scientific purposes, September 22, 2010 and ARRIVE guidelines [20]. The research concept was approved by the local ethics committee (meeting minutes No. 10 of 12/12/2020).

5.3. Cerebral ischemia model

Cerebral ischemia was modeled by the method of irreversible occlusion of the middle cerebral artery. The course of the operation: in anesthetized animals (chloral hydrate 350 mg / kg, intraperitoneally), on the depilated area below and to the right of the eye, the skin was dissected and the muscles were moved apart. Then the process of the zygomatic bone was removed and the skull was exposed. Next, a burr was used to make a trepanation hole above the intersection of the middle cerebral artery and the olfactory tract, the dura mater was removed, and the artery was electrocoagulated, followed by cutting to avoid vessel recanalization, and the wound was sutured in layers. The seam was treated with an antiseptic solution. Before awakening, the animals were left under a warming lamp [21].

CoQ10 (Hunan Warrant Pharm, China) at a dose of 200 mg / kg (per os) was used as a reference drug [22]. The compounds under study were administered at a dose of 40 mg / kg orally for 3 days after modeling brain ischemia (the reference was administered in the same way) [9]. The compounds under study were administered to intact animals for 10 days [9].

5.4. Biomaterial preparation

When studying the activity of mitochondrial complex III, the brain of animals was used as a biomaterial, which was homogenized in the isolation medium (1 mmol EGTA + 215 mmol mannitol + 75 mmol sucrose + 0.1% BSA solution + 20 mmol HEPES with pH 7.2). The resulting homogenate was centrifuged at 1100 g for 2 minutes. Secondary supernatant in the amount of 700 μl was transferred into Eppendorf tubes, mixed with 75
μl of 10% Percoll and centrifuged at 18000g for 10 minutes. The pellet was resuspended in 1 ml of isolation medium and centrifuged for 5 minutes at 10,000 g [23].

5.5. Methods for assessing the activity of the mitochondrial complex III

The activity of complex III was assessed by a spectrophotometric method based on an increase in the optical density (550 nm) of a solution containing succinate, cytochrome C, rotenone, and an analyzed sample. The activity of the complex was expressed in terms of the protein concentration in the analyzed sample. The protein content was estimated according to the Bradford method [24].

5.6. Methods for calculating quantum chemical parameters

Calculation of quantum chemical parameters: Mulliken charges (a.u.) on atoms forming a specific structure, bond numbers (Nμ), theoretical valence (Vμ), unsaturation index (IUA), electron density, free valence index (Fμ), were calculated by the semiempirical PM7 method (WinMopac 2016) using an IntelXeonES-1620 3.5 Hz processor, 20 GB of RAM.

5.7. Statistical Methods

Statistical processing of the research results was carried out using the applied software packages MS Excel 2013 and STATISTICA 6.0 (StatSoft, USA) for Windows. Data were expressed as M (mean) ± SEM (standard error of the mean). Statistically significant differences between groups were assessed by one-way analysis of variance (ANOVA) with post-Newman-Keuls post-processing at a significance level of p <0.05. Correlation analysis was performed using Spearman's test.

Acknowledgements: The study was funded by the authors.

Author contributions: Concept – V.R., E.O., D.P.; Design – V.R., E.O., D.P.; Supervision – E.O.; Resources – V.R., E.O., D.P.; Materials – V.R., E.O., D.P.; Data Collection and/or Processing – V.R., D.P.; Analysis and/or Interpretation – V.R., E.O., D.P.; Literature Search – E.O.; Writing – V.R., E.O., D.P.; Critical Reviews – V.R., E.O., D.P.;

Conflict of interest statement: Authors declare no conflict of interest

Ethical approval: The study was approved by the local ethics committee (protocol No. 10 of 12/12/2020).

REFERENCES

[1] Diebold LP, Gil HJ, Gao P, Martinez CA, Weinberg SE, Chandel NS. Mitochondrial complex III is necessary for endothelial cell proliferation during angiogenesis. Nat Metab. 2019;1(1):158-171. [CrossRef]

[2] Chandel NS. Mitochondrial complex III: an essential component of universal oxygen sensing machinery? Respir Physiol Neurobiol. 2010;174(3):175-181. [CrossRef]

[3] Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U, Schumacker PT. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab. 2005;1(6):401-408. [CrossRef]

[4] Zhao RZ, Jiang S, Zhang L, Yu ZB. Mitochondrial electron transport chain, ROS generation and uncoupling (Review). Int J Mol Med. 2019;44(1):3-15. [CrossRef]

[5] Orellana-Urzúa S, Rojas I, Líbano L, Rodrigo R. Pathophysiology of Ischemic Stroke: Role of Oxidative Stress. Curr Pharm Des. 2020;26(34):4246-4260. [CrossRef]

[6] Tarakhovsky YuS, Kim YuA, Abdrasilov BS, Muzafarov EN, Flavonoids: biochemistry, biophysics, medicine, Synchrobook, Moscow, Russia, 2013.

[7] Reis J, Gaspar A, Milhazes N, Borges F. Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances. J Med Chem. 2017; 60: 7941-7957. [CrossRef]

[8] Gomes A, Freitas M, Fernandes E, Lima JL. Biological activities of 2-styrylchromones. Mini Review. Med Chem. 2018;10(1):1-7. [CrossRef]

[9] Pozdnyakov DI, Voronkov AV, Rukovitsyna VM. Chromone-3-aldehyde derivatives restore mitochondrial function in rat cerebral ischemia. Iran J Basic Med Sci. 2020; 23(9): 1172-1183. [CrossRef]
Chromone derivatives restore the activity of mitochondrial complex III

1. Santos CMM, Silva VLM, Silva AMS. Synthesis of Chromone-Related Pyrazole Compounds. Molecules. 2017;22(10):1665. [CrossRef]

2. Cheng YC, Sheen JM, Hu WL, Hung YC. Polyphenols and Oxidative Stress in Atherosclerosis-Related Ischemic Heart Disease and Stroke. Oxid Med Cell Longev. 2017;2017:8526438. [CrossRef]

3. Bennion DM, Steckelings UM, Sumners C. Neuroprotection via AT2 receptor agonists in ischemic stroke. Clin Sci (Lond). 2018;132(10):1055-1067. [CrossRef]

4. Lv J, Guan W, You Q, Deng L, Zhu Y, Guo K, Gao X, Kong J, Yang C. RIPc provides neuroprotection against ischemic stroke by suppressing apoptosis via the mitochondrial pathway. Sci Rep. 2020;10(1):5361. [CrossRef]

5. Fernandez-Vizarra E, Zeviani M. Mitochondrial complex III Rieske Fe-S protein processing and assembly. Cell Cycle. 2018;17(6):681-687. [CrossRef]

6. Chinopoulos C. Mitochondrial permeability transition pore: Back to the drawing board. Neurochem Int. 2018;117:49-54. [CrossRef]

7. Chandel NS. Mitochondrial complex III: an essential component of universal oxygen sensing machinery? Respir Physiol Neurobiol. 2010;174(3):175-181. [CrossRef]

8. Li Z, Forshaw TE, Holmila RJ, Vance SA, Wu H, Poole LB, Furdui CM, King SB. Triphenylphosphonium-Derived Protein Sulfenic Acid Trapping Agents: Synthesis, Reactivity, and Effect on Mitochondrial Function. Chem Res Toxicol. 2019;32(3):526-534. [CrossRef]

9. Agadzhanyan VS, Oganesyan ET, Abaev VT. Purposeful search for a leader compound in a series of cinnamic acid derivatives with antiradical activity. Rus J Pharm Chem. 2010; 44(7):21-26 [CrossRef]

10. Nohara A, Umetani T, Sanno Y. Studies on antianaphylactic agents. 1. A facile synthesis of 4-oxo-4H-1-benzopyran-3-carboxaldehydes by Vilsmeier reagents. Tetrahedron. 1974; 30:3553-3561. [CrossRef]

11. Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Würbel H. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biology. 2020;18(7): e3000410. [CrossRef]

12. Tamura A, Graham DI, McCulloch J, Teasdale GM. Focal cerebral ischaemia in the rat: 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. J Cereb Blood Flow Metab. 1981;1(1):53-60. [CrossRef]

13. Mustafa HN, Hegazy GA, Awdan SAE, AbdelBaset M. Protective role of CoQ10 or L-carnitine on the integrity of the myocardium in doxorubicin induced toxicity. Tissue Cell. 2017;49(3):410-426. [CrossRef]

14. Voronkov AV, Pozdnyakov DI, Nigaryan SA, Khouri EI, Miroshnichenko KA, Sosnovskaya AV, Olokhova EA. Evaluation of the mitochondria respirometric function in the conditions of pathologies of various genoses. Pharm. Pharmacol. 2019;7(1):20-31. [CrossRef]

15. Spinazzi M, Casarin A, Pertegato V, Salviati L, Angelini C. Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells. Nat Protoc. 2012;7:1235-1246. [CrossRef]